Inoviem Scientific

What Inoviem Scientific does

Inoviem Scientific is a privately held French contract research organization (CRO) founded in 2011 in Strasbourg (Illkirch-Graffenstaden), offering bioanalytical and translational pharmacology services to big pharmaceutical companies, biotechnology firms, and academic research institutions. The company is built around a portfolio of proprietary, label-free biophysical and proteomics platforms — NPOT® (Nematic Protein Organization Technique), PIMS® (Physiological Intermolecular Modulation Spectroscopy), LIPS (Ligand Induced Phase Shift), and the InOPERA® database/software — that operate directly on human pathological tissue under physiological conditions, preserving the native molecular structure of test compounds and enabling target identification, mechanism-of-action elucidation, patient stratification, biomarker discovery, lead compound selection, and indication prioritization.

The business model is professional-services / fee-for-service: Inoviem delivers project-based, quote-based CRO engagements rather than standardized product offerings, with no public pricing or rate cards. More than 200 discovery, preclinical, and clinical studies have been completed across nearly all major therapeutic areas, and the service offering was recently extended with the Drug Upgrade® drug-repurposing methodology. Underlying infrastructure includes 800+ m² of BSL2-capable laboratories at the Strasbourg Bioparc, a Bruker timsTOF Pro with TIMS/PASEF for proteomics, Biacore SPR, and a dedicated tissue-collection laboratory at the Kyrgyz State Medical Academy (KSMA) in Bishkek that provides direct, prospective access to treatment-naive patient samples.

Go-to-market is direct enterprise field sales supported by conference-driven engagement (DDIP, BIO International, Swiss Biotech Day, Discovery Europe/US) and a community-led thought-leadership channel (on-demand webinars, podcast appearances, case studies). Named enterprise clients include Johnson & Johnson, Chiesi Farmaceutici, ITEOS, and Takeda Pharmaceuticals; named academic partners include the University of Erlangen-Nürnberg, the University of Strasbourg, and KSMA. Recent strategic moves include the 2021 acquisitions of ArkAb and B Cell Design, the 2023 launch of the Drug Upgrade® methodology, and the October 2025 co-development agreement with Swiss biotech abc biopply ag for an integrated biopsy-plus-3D-multi-organoid oncology service.

Name

Inoviem Scientific

Legal name

Inoviem Scientifc SAS

Website

https://inoviem.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Inoviem Scientific is a Strasbourg-based bioanalytical CRO that provides label-free translational pharmacology services (target deconvolution, MoA elucidation, patient stratification, biomarker discovery) to big pharma, biotech, and academic clients using proprietary NPOT®, PIMS®, and LIPS platforms on human pathological tissue.

Ownership category

akta.pro rank

Product category

Bioanalytical Contract Research Services

SIC

Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

akta.pro secondary industries

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

• Bioanalytical CRO services
• Translational pharmacology
• Label-free biophysics
• Drug target identification
• Preclinical drug development

Headquarters

HQ city

Illkirch-graffenstaden

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. CRO Bioanalytical R&D Services: Fee-for-service bioanalytical R&D and CRO services delivered to pharmaceutical and biotechnology clients. Project-based engagements covering target deconvolution, target validation & engagement, indication prioritization, lead compound selection, patient cohort stratification, biomarker discovery, SPR & proteomics, and human biological samples provision. 200+ discovery, preclinical and clinical studies completed to date.
2. Co-developed Preclinical CRO Service (with abc biopply): Jointly developed preclinical service integrating Inoviem's direct access to fresh patient tumor biopsies (Pharmacology on the Spot) with abc biopply's proprietary 3D multi-organoid technology. Launched initially for triple-negative breast cancer (TNBC) biopsies, expandable to other indications.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Inoviem Scientific is a bioanalytical Contract Research Organization (CRO) that delivers label-free translational pharmacology services to pharmaceutical and biotechnology companies. Using its proprietary NPOT®, PIMS®, and LIPS platforms, the company performs drug target identification, target validation, mechanism of action (MoA) deconvolution, patient stratification, and biomarker discovery directly on human pathological tissues. The service offering spans drug discovery through clinical development, supported by direct access to fresh, treatment-naive patient samples via a partnership with the Kyrgyz State Medical Academy.

Product overview

Inoviem Scientific operates a platform-plus-modules architecture centered on proprietary label-free biophysical technologies used directly on human pathological tissues. The core platforms are NPOT® (Nematic Protein Organization Technique), PIMS® (Physiological Intermolecular Modulation Spectroscopy), and LIPS (Ligand Induced Phase Shift), supported by the InOPERA® proprietary database for data analysis. These platforms power an integrated suite of drug development services spanning Target & MoA Deconvolution, Target Validation & Engagement, Indication Prioritization, Patient Cohort Stratification, Lead Compound Selection, Biomarker Discovery, SPR & Proteomics, and Human Biological Samples Provision. The company positions itself as the only bioanalytical CRO using label-free technologies under physiological conditions and in human tissue, working with big pharma, biotechs, and research institutions to deliver translational pharmacology services across nearly all therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

• NPOT®: Nematic Protein Organization Technique — a biophysical, label-free platform that maps how drugs interact with proteins in their native, unaltered state to identify targets, interaction networks, and biomarkers.
• PIMS®
• LIPS
• InOPERA®
• Drug Upgrade®

Products and services

• Target & MoA Deconvolution Service that defines a drug candidate's mechanism of action (MoA) by leveraging proprietary NPOT® technology to isolate and identify the entire network of proteins (ON and OFF targets) the compound interacts with, using patient-derived evidence from human pathological tissues. For pharmaceutical and biotechnology R&D teams needing MoA elucidation.
• Target Validation & Engagement Service for validating targets in chosen models (cell line, primary cells, iPSCs, or animal models) and conducting dose-dependency target engagement studies as proof of concept using the LIPS platform. Combined NPOT® and proteomic platform enables analysis of complete protein interactome, including on- and off-target interactions. For pharma and biotech discovery teams.
• Indication Prioritization & Repositioning Service that fast-tracks the development of new treatments or repositions existing marketed drugs, identifying pathologies where a compound may be more effective. Leverages NPOT® and LIPS platforms in combination with human pathological tissues from various diseases to determine the most suitable pathology for repositioning a given molecule and assess safety and efficacy. For pharma and biotech pipeline teams.
• Patient Cohort Stratification Service that uses the PIMS® platform to select patients whose samples show they are likely to respond well to specific targeted medicines, supporting the development of precision treatments. Combines PIMS® patient stratification, NPOT® Mode of Action identification in responders vs non-responders, and predictive biomarkers identification. For clinical development and translational pharmacology teams.
• Lead Compound Selection Service leveraging NPOT® technology to identify the most promising lead compound from a pool of potential candidates within four weeks of study. Enables rapid druggability assessment, rapid lead identification, reduced time and cost, target-based ranking of remaining compounds, and identification of back-up options. For medicinal chemistry and discovery teams.
• Biomarker Discovery Translational pharmacology service that empowers identification of biomarkers and advances clinical developments, using Inoviem's bioanalytical platforms to profile patient samples across multiple matrices.
• SPR & Proteomics Services including Surface Plasmon Resonance (SPR) for kinetics and affinity determination, medium throughput fragment and small molecule screening, binding specificity profiling, and antibody screening. Proteomics services using the Bruker timsTOF Pro with TIMS and PASEF acquisition for deep proteome coverage, post-translational modification analysis, antibody characterization, and label-free quantification. For pharma, biotech, and academic research groups.
• Human Biological Samples Provision Comprehensive service for prospective tissue collection programs and biobanking across multiple disease areas including oncology, respiratory, fibrosis, inflammatory, CNS/neurodegenerative, autoimmune, metabolic, dermatology, ophthalmology, and rheumatology. Includes tailored collection and processing with partners such as the Kyrgyz State Medical Academy (KSMA) in Bishkek, Kyrgyzstan. Supports fresh, frozen, fresh-frozen, RNA-later, FFPE, and paraffin-embedded samples; fresh material maintained via portable cell culture system for up to 21 days post-isolation. For pharma, biotech, and academic research groups.
• Co-developed Preclinical CRO Service with abc biopply (3D Multi-Organoid + Fresh Patient Biopsies) Jointly developed and commercialized preclinical CRO service combining Inoviem's fresh patient tumor biopsy access and bioanalytical capabilities with abc biopply's 3D multi-organoid technology for oncology drug development, initially focused on triple-negative breast cancer (TNBC). For pharma and biotech oncology drug developers seeking early-stage translational modeling.

Quantifiable outcome

• 89% positive predictive value (PPV) and 82% negative predictive value (NPV) in predicting vedolizumab response in anti-TNF refractory IBD patients (20-patient cohort); 100% accuracy in ulcerative colitis (n=7) and 77% in Crohn's disease (n=13).
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core / flagship, important, core and minor.

• abc biopply agcore / flagshipStrategic or Co-development Partner · 10 October 2025Strategic collaboration announced 10 October 2025 to develop and commercialize a new preclinical service integrating Inoviem's direct access to fresh patient tumor biopsies (incl. 'Pharmacology on the Spot' method) with abc biopply's proprietary 3D multi-organoid technology™. Initially focused on triple-negative breast cancer (TNBC) biopsies, expandable to other indications. Both companies seeking pharma/biotech partners to leverage the platform for early-stage drug evaluation and translational accuracy between preclinical assays and Phase II/III trials.
• University of Erlangen-Nürnberg (Germany)importantStrategic or Co-development Partner · 1 January 2021Academic collaboration on the prospective IBD vedolizumab study. Together with Takeda Pharmaceuticals GmbH, the university collaborated with Inoviem on the first-time application of PIMS® and NPOT® to anti-TNF refractory IBD patients. 20-patient cohort (13 Crohn's disease, 7 ulcerative colitis); PIMS® achieved 100% prediction accuracy in ulcerative colitis and 77% in Crohn's disease, with overall 89% PPV and 82% NPV.
• Takeda Pharmaceuticals GmbHimportantStrategic or Co-development Partner · 1 January 2021Industry collaboration partner on the prospective IBD vedolizumab study. Takeda co-developed the clinical study design with Inoviem and the University of Erlangen-Nürnberg to predict response to vedolizumab (Entyvio) in anti-TNF refractory IBD patients using PIMS® and NPOT® technologies.
• Kyrgyz State Medical Academy (KSMA)coreImplementation/ SI/ Consulting PartnerClinical-academic partnership providing direct access to patients and prospective tissue collection. Inoviem has established dedicated laboratories at KSMA in Bishkek (Kyrgyzstan) for patient characterization and sample preparation. The Kyrgyz patient population is generally naive to modern treatments (e.g., anti-PD1 monoclonal antibodies) and is highly diverse (individuals from China, Russia, Turkey, India, and native Kyrgyz citizens). Supports collection of oncology, respiratory, fibrosis, inflammatory, CNS/neurodegenerative, autoimmune, metabolic, dermatology, ophthalmology, and rheumatology samples.
• University of Strasbourg (France)importantStrategic or Co-development PartnerAcademic collaboration for the design and synthesis of a series of hydroxychloroquine analogues based on the chemical structures of myeloperoxidase (MPO) and alphaB-crystallin (αB-C). The lead candidate INS-072 was selected for enhanced anti-inflammatory properties and reduced retinopathy, leading to patent application WO2016193503.
• Jean-Paul Ansel (DMS group)minorStrategic or Co-development PartnerBoard Member on Inoviem's Supervisory Board. Mr. Ansel has more than 45 years of international banking and financing experience and leads DMS group, where his expertise has blossomed through acquisition of companies focused on human health and personalized medicine. Provides board-level strategic guidance and corporate finance/industry connections.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Charles River Laboratories: Large global preclinical CRO offering discovery, safety assessment, and bioanalytical services to pharma and biotech. Comparable to Inoviem as a discovery/preclinical CRO customer base, though Charles River operates at vastly greater scale and with broader service breadth.
• Pharmaron: Global CRO/CDMO offering drug discovery, preclinical, and clinical bioanalytical services across therapeutic areas. Comparable to Inoviem in providing integrated discovery and bioanalytical services, though at significantly larger scale with broader geographic footprint.
• WuXi AppTec / WuXi Biology: Large global CRO providing preclinical biology, bioanalytical, and drug discovery services to pharma/biotech. Comparable to Inoviem as a discovery CRO with bioanalytical capabilities, though operating at much larger scale and with broader service portfolio.

Direct peers

• Evotec SE: Integrated drug discovery CRO offering target identification, hit identification, and translational pharmacology across modalities and therapeutic areas. Comparable to Inoviem in providing end-to-end preclinical discovery services to pharma/biotech, with significant overlap in target ID and MoA work.
• Eurofins Discovery: Discovery and bioanalytical CRO division of Eurofins offering in vitro pharmacology, ADME, and proteomics services to pharma. Comparable to Inoviem as a bioanalytical/preclinical CRO serving drug discovery with similar project-based service model.
• Sygnature Discovery: UK-based discovery CRO providing medicinal chemistry, in vitro pharmacology, and DMPK services to pharma and biotech. Comparable to Inoviem as a mid-sized, science-led preclinical CRO serving similar client profiles and therapeutic areas.
• Concept Life Sciences: UK-based discovery and development CRO offering in vitro/in vivo pharmacology, bioanalytical sciences, and biomarker services. Comparable to Inoviem as a mid-sized discovery CRO with bioanalytical specialization serving pharma/biotech clients.

Emerging players

• Reprocell Europe (formerly Cyprotex): Specialized preclinical CRO offering in vitro ADME, bioanalytical, and translational services with focus on human-relevant models. Comparable to Inoviem in providing human-relevant bioanalytical services for drug discovery, though with broader ADME focus.
• Cell Signaling Technology (CST) - Services: Provider of antibodies, assays, and custom proteomics services including biomarker discovery and pathway analysis for translational research. Comparable to Inoviem in offering proteomics and biomarker discovery services, though with broader antibody/reagent focus and greater scale.
• Bionova Scientific: US-based bioanalytical and biologics characterization CRO offering mass spectrometry, SPR, and protein characterization services. Comparable to Inoviem as a specialized bioanalytical CRO using mass spectrometry and SPR for protein-drug interaction studies in translational research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=smk_K0mLYME
• LinkedInlinkedin.com/company/inoviem-scientific

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inoviem Scientific